Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSabre Insurance Group Regulatory News (SBRE)

Share Price Information for Sabre Insurance Group (SBRE)

Share Price is delayed by 15 minutes
Get Live Data
161.60    -2.00 (-1.22%)
Bid:
161.60
Ask:
162.00
Spread: 0.40 (0.248%)
Market Cap: £393.82m
SBRE Live PriceLast checked at - London Stock Exchange

Intraday Sabre Insurance Group Share Chart

Trading Update

22 Oct 2024 07:00

RNS Number : 0295J
Sabre Insurance Group PLC
22 October 2024
 

22 October 2024

Sabre Insurance Group plc

Trading Update

On track for record premium income and strong, on-target profit

Sabre Insurance Group plc (the "Group" or "Sabre"), one of the UK's leading motor insurance underwriters, today provides an update on trading for the period from 1 July 2024 to 30 September 2024.

 

Unaudited

Nine months ended

30 September

 

Year ended

31 December

 

2024

2023

% Change

 2023

Gross written premium - Motor Vehicle

£165.6m

£140.5m

18%

£199.0m

Gross written premium - Motorcycle

£8.2m

£10.7m

(23%)

£11.8m

Gross written premium - Taxi

£12.7m

£11.0m

15%

£14.3m

Gross written premium - Total

£186.5m

£162.2m

15%

£225.1m

Post-dividend solvency capital ratio

195%

191%

 

171%

 

Key Highlights

- Gross Written Premium up 15% against the same period in 2023, on-track to deliver record Gross Written Premium for the year

- Continued to increase rates to cover elevated claims inflation, in contrast to the wider market

- Policies continue to be written at target margins - underpinning profitable growth for this year and positioning Sabre well into 2025

- Focus on disciplined underwriting reflected in expectation of a profitable out-turn across all product lines

- Continued strong capital generation supports confidence in the ability to pay an attractive dividend for the year

- Policy count as at 30 September 2024: Motor - 230k (30 September 2023: 222k), Motorcycle - 38k (30 September 2023: 45k), Taxi - 11k (30 September 2023: 13k)

 

Capital Markets Event

- A capital markets session for investors and analysts, focussed on how our strategy and business model will deliver growth and value for our shareholders in the medium-term, will be held on 5th December 2024

 

Market trends

- Some signs of claims inflation moderating, but remains at a high single-digit level

- Despite this, increasing competition for volume in the mass-market is evident in clear signs of market price reductions

- However, level of market discounting far lower than the extreme price movements seen in recent years suggesting a more stable trading environment

- We continue to expect market prices will need to increase to reflect current levels of inflation

- We note the recent announcement of a cross-government motor insurance taskforce, supported by industry experts, formed to help identify the factors behind rapidly rising premiums. We are pleased that this is primarily focussing on options to tackle the underlying cost inflation driving premium increases

- We also note the Financial Conduct Authority's recently announced premium finance market study. We look forward to engaging with the regulator as appropriate, and can confirm our full compliance with fair value rules and our belief that we have very limited regulatory exposure. The proportion of our profits expected to be generated through premium finance income remains minimal

 

Full-year profit guidance reaffirmed, slight softening in gross written premium

- We continue to anticipate strong year-on-year premium growth, and profit in line with current market expectations

- We expect our year-on-year premium growth to be moderated slightly and to be in-line with our view of high single digit claims inflation

 

Geoff Carter, Chief Executive Officer of Sabre, commented:

"I'm pleased with our performance at the Q3 stage and look forward with confidence to a strong full-year result. Importantly, our resolute price discipline means we expect to continue this good performance in future periods.

We have seen clear signs that market pricing has softened considerably during the summer. Our view is that market price movements outstrip any potential short-term benefits from a slight softening in claims inflation. We remain confident in our view on inflation and that market pricing will have to reflect this in due course.

Our proven, disciplined strategy has enabled us to adapt to changing market conditions successfully and rapidly. We were able to grow very strongly in attractive market conditions in H1, and then to accept slightly lower, but still good, volumes in Q3.

I am also excited that we are now completing the foundation work that will support our multi-year growth strategy. I look forward to discussing this at an update session for analysts and investors in December and updating on our progress in future results presentations."

 

Investor enquiries

01306 747 272

Sabre Insurance Group plc

Geoff Carter / Adam Westwood

Media enquiries

020 7353 4200

Teneo

sabre@teneo.com

James Macey White / Ffion Dash

 

LEI Code: 2138006RXRQ8P8VKGV98

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTFEUFAFELSEES
Date   Source Headline
3rd Jul 20243:40 pmRNSHolding(s) in Company
19th Jun 202412:28 pmRNSAppointment of Non-executive Director
14th Jun 20249:50 amRNSDirector/PDMR Shareholding
11th Jun 202411:54 amRNSDirector/PDMR Shareholding
11th Jun 202410:17 amRNSDirector/PDMR Shareholding
10th Jun 20244:16 pmRNSHolding(s) in Company
6th Jun 202412:52 pmRNSDirector/PDMR Shareholding
30th May 20242:00 pmRNSDirector/PDMR Shareholding
23rd May 202411:08 amRNSResult of AGM
23rd May 20247:00 amRNSTrading Update
22nd May 20241:59 pmRNSDirector/PDMR Shareholding
21st May 20242:46 pmRNSHolding(s) in Company
20th May 20248:23 amRNSAppointment of Senior Independent Director
15th May 20242:24 pmRNSHolding(s) in Company
13th May 202412:23 pmRNSDirector/PDMR Shareholding
23rd Apr 20244:00 pmRNSHolding(s) in Company
22nd Apr 20243:22 pmRNSHolding(s) in Company
19th Apr 20248:51 amRNSChair Appointment
18th Apr 202411:22 amRNSDirector Declaration
11th Apr 202412:41 pmRNSDirector/PDMR Shareholding
11th Apr 202412:07 pmRNSDirector/PDMR Shareholding
9th Apr 20242:44 pmRNSDirector/PDMR Shareholding
5th Apr 20243:48 pmRNSNotice of AGM
21st Mar 202412:30 pmRNSDirector/PDMR Shareholding
19th Mar 20247:00 amRNSFull-year results 2023
13th Mar 20249:33 amRNSNotice of Results
12th Mar 20242:16 pmRNSDirector/PDMR Shareholding
12th Mar 202412:14 pmRNSDirector Declaration
16th Feb 20241:52 pmRNSHolding(s) in Company
15th Feb 20247:00 amRNSTrading Statement
13th Feb 20242:18 pmRNSDirector/PDMR Shareholding
11th Jan 202411:11 amRNSDirector/PDMR Shareholding
20th Dec 20232:24 pmRNSHolding(s) in Company
12th Dec 202312:03 pmRNSDirector/PDMR Shareholding
28th Nov 20234:27 pmRNSDirectorate Change
27th Nov 20234:42 pmRNSRemuneration Committee Chair Appointment
22nd Nov 20238:51 amRNSNotification of cyber incident
20th Nov 20237:00 amRNSDeath of Chair
13th Nov 202311:44 amRNSDirector/PDMR Shareholding
19th Oct 20237:00 amRNSTrading Update
11th Oct 202312:52 pmRNSDirector/PDMR Shareholding
25th Sep 20233:39 pmRNSDirector/PDMR Shareholding
21st Sep 202311:48 amRNSDirector/PDMR Shareholding
14th Sep 20232:25 pmRNSHolding(s) in Company
13th Sep 202310:00 amRNSDirector/PDMR Shareholding
13th Sep 20239:33 amRNSDirectorate Change
11th Aug 202310:07 amRNSDirector/PDMR Shareholding
3rd Aug 20237:00 amRNSHalf-year Report 2023
25th Jul 20238:53 amRNSDirector Declaration
11th Jul 20232:57 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.